Breast Cancer | Specialty

Treatment Options for HER2+, ER+ Metastatic Breast Cancer

March 2nd 2022

A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.

Special HER2+ mBC Populations: HR+ or HER2-Low Patients

March 2nd 2022

Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.

Next-Generation Antibody-Drug Conjugates Make Their Mark in Breast Cancer

March 2nd 2022

Dr. Traina on Results of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 1st 2022

Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Fox Chase Cancer Center’s Jonathan Chernoff Awarded Pennsylvania Breast Cancer Coalition Grant

March 1st 2022

Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, was recently awarded a $50,000 grant from the Pennsylvania Breast Cancer Coalition.

SABCS Generates Discussion Around SERDs, CDK4/6 Inhibitors, and ADCs in Breast Cancer

March 1st 2022

From early phase 1/2 to pivotal phase 3 data, the 2021 San Antonio Breast Cancer Symposium was full of exciting research with selective estrogen receptor degraders, CDK4/6 inhibitors, and antibody-drug conjugates.

Potential Role of Surgery in HER2+ Metastatic Breast Cancer

February 23rd 2022

Shared insight on the potential role for surgery in the setting of HER2+ metastatic breast cancer in the context of pharmacologic therapy.

SABCS 2021: Small Molecule Clinical Trials in R/R HER2+ mBC

February 23rd 2022

Rounding out their conversation on SABCS 2021, experts discuss small molecule–based treatment strategies for relapsed/refractory HER2+ metastatic breast cancer.

Investigators Explore Metformin to Prevent Cancers in Li-Fraumeni Syndrome Carriers

February 22nd 2022

Individuals with Li-Fraumeni Syndrome, a rare hereditary condition, are at increased risk for a wide spectrum of malignancies, including breast cancer and sarcomas. Investigators are working to determine whether metformin, a drug indicated for diabetes and infertility caused by polycystic ovarian syndrome, can prevent cancers in LFS carriers.

Dr. Abdou on the Significance of the DESTINY-Breast03 Trial in HER2-Positive Breast Cancer

February 21st 2022

Yara Abdou, MD, discusses the significance of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

February 21st 2022

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Trastuzumab Deruxtecan Significantly Improves PFS, OS in HER2-Low Metastatic Breast Cancer

February 21st 2022

Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.

A Focus on Patient-First Care Drives Breast Cancer Investigator to Success

February 21st 2022

Joyce A. O’Shaughnessy, MD, the 2016 Giant of Cancer Care® for Community Outreach/Education, explains her continued commitment to impacting change in the space and aiding other oncologists.

First-in-Class AR Agonist Opens Doors for ER-Positive Metastatic Breast Cancer

February 17th 2022

Androgen recepter positivity serves as an independent predictor of beneficial outcomes in breast cancer.

Daily Aspirin Does Not Prevent Recurrence in High-Risk, HER2-Negative Breast Cancer

February 16th 2022

The administration of daily aspirin did not improve invasive disease-free survival in patients with high-risk, HER2-negative breast cancer.

Practical Advice on the Use of ctDNA Testing in Breast Cancer

February 16th 2022

Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.

Other Clinical Studies on ctDNA Use in Breast Cancer

February 16th 2022

Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.

SABCS 2021: Combination Strategies Under Investigation for R/R HER2+ mBC

February 16th 2022

Considering data from the SABCS 2021 annual meeting, experts discuss novel combination strategies for relapsed/refractory HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Updates on HER2CLIMB and CNS Disease Management

February 16th 2022

A brief review of updated data from HER2CLIMB and discussion on which agents may be best for treating patients with CNS disease.

Shifting Treatment Sequencing Patterns and New Approaches Transform Breast Cancer Paradigm

February 14th 2022

Jennifer M. Matro, MD provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice.